HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Brandon Folkes maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price target from $10 to $18.
HC Wainwright & Co. analyst Brandon Folkes maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price target from $10 to $18.